Danaher Corporation $DHR Position Reduced by Dohj LLC

Key Points

• Dohj LLC has reduced its position in Danaher Corporation (NYSE:DHR) by 62.1%, now holding 1,824 shares valued at $358,000 after selling 2,986 shares during the second quarter.
• Wall Street analysts have a generally positive outlook on Danaher, with seventeen analysts rating it a "Buy" and a consensus price target of $245.63.
• Danaher announced a quarterly dividend of $0.32 per share, with a dividend yield of 0.6%, reflecting an ongoing commitment to shareholder returns.

Dohj LLC reduced its position in Danaher Corporation (NYSE:DHR - Free Report) by 62.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,824 shares of the conglomerate's stock after selling 2,986 shares during the period. Dohj LLC's holdings in Danaher were worth $358,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Hills Bank & Trust Co boosted its position in shares of Danaher by 0.3% during the first quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock worth $3,693,000 after buying an additional 53 shares during the period. Worth Financial Advisory Group LLC lifted its holdings in Danaher by 4.6% during the 2nd quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate's stock worth $236,000 after purchasing an additional 53 shares during the last quarter. Sageworth Trust Co boosted its holdings in Danaher by 2.3% in the 1st quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate's stock valued at $493,000 after purchasing an additional 54 shares during the period. 1834 Investment Advisors Co. grew its holdings in shares of Danaher by 3.3% during the 1st quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate's stock worth $342,000 after purchasing an additional 54 shares in the last quarter. Finally, Bruce G. Allen Investments LLC raised its position in Danaher by 13.1% during the second quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate's stock valued at $92,000 after purchasing an additional 54 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on DHR. Guggenheim reaffirmed a "buy" rating and set a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. Royal Bank Of Canada set a $241.00 price target on shares of Danaher in a research note on Tuesday, September 2nd. UBS Group decreased their target price on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a report on Wednesday, July 23rd. Redburn Partners set a $220.00 price target on shares of Danaher in a research note on Wednesday. Finally, Weiss Ratings restated a "hold (c-)" rating on shares of Danaher in a report on Saturday, September 27th. Seventeen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, Danaher has an average rating of "Moderate Buy" and an average price target of $245.63.

Insider Activity

In related news, Director Teri List sold 2,778 shares of the business's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares in the company, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 11.20% of the company's stock.

Danaher Stock Down 1.5%

NYSE DHR opened at $208.63 on Wednesday. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The stock's 50 day moving average is $200.40 and its 200 day moving average is $197.32. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $279.41. The stock has a market cap of $149.39 billion, a PE ratio of 44.39, a P/E/G ratio of 3.02 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating the consensus estimate of $1.64 by $0.16. The business had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. Danaher's quarterly revenue was up 3.4% compared to the same quarter last year. During the same quarter last year, the business earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher's dividend payout ratio is presently 27.23%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.